28 Chapter 1 80. Yan, F. et al. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. PLoS One 9, (2014). 81. Echeverría, F., Ortiz, M., Valenzuela, R. & Videla, L. A. Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging. Prostaglandins Leukotrienes and Essential Fatty Acids vol. 114 28–34 Preprint at https:// doi.org/10.1016/j.plefa.2016.10.001 (2016). 82. Keller, H. et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers (peroxisome proliferator-activated receptor response element/retinoid X receptor response element/acyl-CoA oxidase gene/ nuclear hormone receptors). Proc. Natl. Acad. Sci. USA 90, 2160–2164 (1993). 83. Sanyoto, D. D., Asnawati, A. & Triawanti, T. Effect of DHA Supplementation on the MDA and SOD Levels in Protein Malnourished Rats. in Journal of Physics: Conference Series vol. 1374 (Institute of Physics Publishing, 2019). 84. Stephenson, K. et al. Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition improve cognition: a randomized, tripleblinded, controlled clinical trial. American Journal of Clinical Nutrition 115, 1322–1333 (2022). 85. Piano, V., Palfey, B. A. & Mattevi, A. Flavins as Covalent Catalysts: New Mechanisms Emerge. Trends in Biochemical Sciences vol. 42 457–469 Preprint at https://doi. org/10.1016/j.tibs.2017.02.005 (2017). 86. Jager, E. A. et al. A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands. J Inherit Metab Dis 42, 890–897 (2019). 87. Bentler, K. et al. 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative. Mol Genet Metab 119, 75–82 (2016). 88. Bennett, M. J. Pathophysiology of fatty acid oxidation disorders. Journal of Inherited Metabolic Disease vol. 33 533–537 Preprint at https://doi.org/10.1007/s10545-0109170-y (2010). 89. Couce, M. L. et al. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: Regional experience and high incidence of carnitine deficiency. Orphanet J Rare Dis 8, (2013). 90. Touw, C. M. et al. In vitro and in vivo consequences of variant medium-chain acyl-CoA dehydrogenase genotypes. Orphanet J Rare Dis 8, (2013). 91. Derks, T. G. J. et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: Clinical presentation and outcome. Journal of Pediatrics 148, (2006). 92. Touw, C. M. L. et al. Risk stratification by residual enzyme activity after newborn screening for medium-chain acyl-CoA dehyrogenase deficiency: Data from a cohort study. Orphanet J Rare Dis 7, (2012). 93. Heales, S. J. R. et al. Production and Disposal of Medium-chain Fatty Acids in Children with Medium-chain Acyl-CoA Dehydrogenase Deficiency. J. Inher. Metab. Dis vol. 17 (1994).
RkJQdWJsaXNoZXIy MTk4NDMw